Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.

	Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.
	Bai, Chunmei ; Xu, Jianming ; Shen, Lin ; Li, Jie ; Zhou, Zhiwei ; Chi, Yihebali ; Li, Zhiping ; Xu, Nong ; Li, Enxiao ; Liu, Tianshu
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2020-05-20
卷号	38
ISSN号	0732-183X
资助项目	Hutchison MediPharma Limited
WOS研究方向	Oncology
语种	英语
出版者	AMER SOC CLINICAL ONCOLOGY
WOS记录号	WOS:000560368302226
资助机构	Hutchison MediPharma Limited
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/104220]
专题	中国科学院合肥物质科学研究院
作者单位	1.Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China 2.Zhejiang Canc Hosp, Hangzhou, Peoples R China 3.Hutchis MediPharma Ltd, Shanghai, Peoples R China 4.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China 5.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China 6.Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China 7.Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Peoples R China 8.Jiangsu Canc Hosp, Nanjing, Peoples R China 9.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 10.Peking Union Med Coll Hosp, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Bai, Chunmei,Xu, Jianming,Shen, Lin,et al. Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY,2020,38.
APA	Bai, Chunmei.,Xu, Jianming.,Shen, Lin.,Li, Jie.,Zhou, Zhiwei.,...&Su, Weiguo.(2020).Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors..JOURNAL OF CLINICAL ONCOLOGY,38.
MLA	Bai, Chunmei,et al."Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.".JOURNAL OF CLINICAL ONCOLOGY 38(2020).